TriSalus Life Sciences is a clinical-stage oncology company developing treatments and devices for cancer. The company operates in two main business segments: TriNav, a proprietary medical device that delivers chemotherapy drugs regionally to tumors and has received FDA clearance for commercialization, and nelitolimod, a drug candidate in clinical development for cancer indications. TriSalus generates revenue primarily through sales of TriNav devices to hospitals and healthcare providers under consignment agreements, while expecting future revenue from nelitolimod upon regulatory approval and successful commercialization; the company also receives milestone payments and royalties under its agreement with Dynavax related to nelitolimod development.